

# Recombinant Human IL-7 Protein

#### **Product Name**

Recombinant Human IL-7 Protein

#### **Size/Catalog Number**

 $50\mu g$  / GMP-TL506-0050  $100\mu g$  / GMP-TL506-0100

#### **Product Information**

Synonyms: Interleukin-7, IL7
Accession: Uniprot P13232-1
Expressed Region: Asp26-His177

Fusion Tag: Human IgG1 Fc fragment fused to C-terminus

**Expression system:** CHO cells

Predicted Molecular weight: 43.8 kDa

**Purity:** > 95% as determined by SDS-PAGE and HPLC **Endotoxin:** < 0.01 EU per 1 µg of protein (LAL method)

Activity: Exhibits dose-dependent proliferation of PHA-activated PBMCs with an ED50 of

0.5-20 ng/mL and a specific activity  $> 1.0 \times 10^7 \text{ IU/mg}$ .

Form: Lyophilized from sterile 20mM phosphate-buffered saline (PBS), pH 7.4, normally

containing 6–8% (w/v) mannitol as protectant

## **Background**

The recombinant human IL-7-Fc fusion protein is a glycosylated functional dimer produced in CHO expression systems, engineered with a C-terminal human IgG1 Fc domain to enhance protein stability and receptor clustering efficacy. As a pivotal member of the IL-2 cytokine family, IL-7 activates the JAK1/JAK3-STAT5 signaling cascade via its heterodimeric receptor (IL- $7R\alpha/\gamma c$ ), driving survival, proliferation, and differentiation of T/B/NK cells while maintaining lymphocyte homeostasis through Bcl-2-mediated anti-apoptotic mechanisms and promoting CD4+/CD8+ double-positive T-cell maturation during thymic development. In cell therapy manufacturing, this fusion protein serves as a critical culture additive to enhance CAR-T cell metabolic fitness and memory phenotype formation through sustained PI3K-AKT-mTOR pathway activation. It synergizes with IL-15 to suppress exhaustion markers (e.g., PD-1/TIM-3) while supporting hematopoietic stem cell differentiation into functional lymphoid progenitors, thereby improving the persistence and antitumor efficacy of adoptive immune cell products. The Fc-mediated dimeric configuration mimics native membrane-bound IL-7 bioactivity and optimizes pharmacokinetic profiles through extended serum half-life.

## **Stability & Storage**

**Lyophilized powder**: Stable for 12 months at -80°C or 6 months at -20°C when stored in the original sealed container under desiccant.

**Reconstitution:** Dissolve in sterile Water for Injection, 0.9% NaCl, or PBS (pH 7.4) maintaining final concentration ≥100 μg/mL to prevent adsorption.

Handling: Aliquot to avoid repeated freeze-thaw cycles.

#### References



- 1. Aliyari Z, Alemi F, Brazvan B, Tayefi Nasrabadi H, Nozad Charoudeh H. CD26+ Cord Blood Mononuclear Cells Significantly Produce B, T, and NK Cells. Iran J Immunol. 2015 Mar;12(1):16-26.
- 2. Kim HR, Hwang KA, Park SH, Kang I. IL-7 and IL-15: biology and roles in T-Cell immunity in health and disease. Crit Rev Immunol. 2008;28(4):325-39.
- 3. Su N, Shi SX, Zhu X, Borazanci A, Shi FD, Gan Y. Interleukin-7 expression and its effect on natural killer cells in patients with multiple sclerosis. J Neuroimmunol. 2014 Nov 15;276(1-2):180-6.

## **Intended Us**

For research and manufacturing purposes only.